A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Sponsor: Janssen Research & Development, LLC
A observational or N/A phase clinical study on Prostatic Neoplasms, this trial is ongoing. The trial is conducted by Janssen Research & Development, LLC and has accumulated 61 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)Niraparib is an orally available, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. AA is a pro-drug of abiraterone which selectively inhibits the enzyme 17 alpha-hydroxylase/C17,20-lyase (CYP17), that is found in the testes and adrenals (leading to systemic inhibition of testosterone production), as well as in prostate tissues and tumors. The rationale of the study is to investigate the various strengths and formulations of niraparib and AA plus prednisone or prednisolone (P) in metastatic castration resistant prostate cancer (mCRPC) participants with and without homologous recombination repair (HRR) gene alterations. In participants with metastatic prostate cancer, DNA-repair anomalies are found in approximately 15 percent (%) to 20% of tumors. This study consists 4 periods: screening phase (up to 21 days); treatment phase (up to 22 days); extension and long-term extension phases (from day 23 until discontinuation); and post-treatment follow up phase (end of treatment \[EoT\] visit within 30 days after the last dose of study treatment). Total duration of study is up to 1.4 years. Efficacy, safety, pharmacokinetics (PK), and biomarkers will be assessed at specified time points during this study. Participants safety will be monitored throughout the study.
Niraparib is an orally available, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. AA is a pro-drug of abiraterone which selectively inhibits the enzyme 17 alpha-hydroxylase/C17,20-lyase (CYP17), that is found in the testes and adrenals (leading to systemic inhibition of testosterone production), as well as in prostate tissues and tumors. The rationale of the study is to investigate the various strengths and formulations of niraparib and AA plus prednisone or prednisolone (P) in metastatic castration resistant prostate cancer (mCRPC) participants with and without homologous recombination repair (HRR) gene alterations. In participants with metastatic prostate cancer, DNA-repair anomalies are found in approximately 15 percent (%) to 20% of tumors. This study consists 4 periods: screening phase (up to 21 days); treatment phase (up to 22 days); extension and long-term extension phases (from day 23 until discontinuation); and post-treatment follow up phase (end of treatment \[EoT\] visit within 30 days after the last dose of study treatment). Total duration of study is up to 1.4 years. Efficacy, safety, pharmacokinetics (PK), and biomarkers will be assessed at specified time points during this study. Participants safety will be monitored throughout the study.
Status Flow
Change History
61 versions recorded-
Apr 13, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE1 → None
-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE1
-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
▶ Show 56 earlier versions
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE1
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and abiraterone acetate (AA) at steady state under modified fasted conditions in participants with metastatic castration-resistant prostate cancer (mCRPC).
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , Chisinau, Moldova , Gdansk, Poland , Ghent, Belgium , Kyiv, Ukraine , Madrid, Spain , Madrid, Spain , Málaga, Spain , Newcastle upon Tyne, United Kingdom , Rotterdam, Netherlands and 6 more locations